Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO , May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
SAN DIEGO , April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company's Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma Inc., a biopharmaceutical company focused
SAN DIEGO , March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company's Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc.
SAN DIEGO , March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET .
Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million Conference call today at 5:00 p.m.
Retrophin Joins Participants from Around the World in Recognizing Rare Disease Day ® 2017 SAN DIEGO (February 28, 2017) – Retrophin, Inc. (NASDAQ: RTRX) today joins patients, advocates, healthcare professionals, researchers, public health authorities and the biopharmaceutical
SAN DIEGO , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
SAN DIEGO , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced William "Bill" Rote, Ph.D. has been appointed senior vice president, research and development, effective immediately. Dr. Rote will oversee all aspects of the Company's R&D organization, with special focus
FDA discussions on sparsentan planned for January; RE-024 advancing with Phase 3 trial for the treatment of PKAN Preliminary Full-Year 2016 Revenue of Approximately $134 Million SAN DIEGO , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary
